Overview

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Status:
NOT_YET_RECRUITING

Trial end date:
2027-09-19

Target enrollment:

Participant gender:

Summary

This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.

Phase:

PHASE1

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Biopsy
CX 5461
Magnetic Resonance Spectroscopy
Specimen Handling
Spinal Puncture